Table 3.

Progressively adjusted models of change in aortic pulse wave velocity from baseline to 6 months (n=109)

ModelGeometric Mean (95% Confidence Interval)Percentage Change from Baseline (95% Confidence Interval)P Value of Change
Unadjusted
 Atenolol7.23 (6.74 to 7.76)−9.3 (−18.5 to −0.2)0.04
 Lisinopril7.06 (6.57 to 7.58)5.5 (−4.6 to 15.6)0.28
 Between-drug difference−0.06 (−0.13 to 0.08)14.8 (1.2 to 28.5)0.03
 Heart rate–adjusted between-drug difference−0.02 (−0.12 to 0.08)20.7 (5.4 to 36.1)<0.01
Model 1: Age, sex, and race adjusted
 Atenolol4.95 (3.89 to 6.29)−9.3 (−18.4 to −0.2)0.04
 Lisinopril4.83 (3.79 to 6.15)5.7 (−4.3 to 15.7)0.26
 Between-drug difference−0.02 (−0.12 to 0.07)15 (1.5 to 28.5)0.03
 Heart rate–adjusted between–drug difference−0.02 (−0.15 to 0.07)18.5 (3.3 to 33.7)0.02
Model 2: Plus diabetes, CVD, and smoking adjusted
 Atenolol4.8 (3.75 to 6.14)−8.7 (−17.7 to 0.4)0.06
 Lisinopril4.75 (3.71 to 6.09)5.6 (−4.3 to 15.5)0.27
 Between-drug difference−0.01 (−0.10 to 0.08)14.3 (0.8 to 27.7)0.04
 Heart rate–adjusted between-drug difference−0.01 (−0.10 to 0.09)17.2 (2.1 to 32.2)0.03
Model 3: Plus baseline ambulatory SBP adjusted
 Atenolol2.9 (1.74 to 4.85)−8.5 (−17.5 to 0.6)0.07
 Lisinopril2.88 (1.72 to 4.8)5.6 (−4.3 to 15.6)0.27
 Between-drug difference−0.01 (−0.10 to 0.08)14.1 (0.6 to 27.6)0.04
 Heart rate–adjusted between-drug difference−0.01 (−0.10 to 0.09)16.9 (1.7 to 32.0)0.03
Model 4: Plus change in ambulatory SBP adjusted
 Atenolol2.6 (1.54 to 4.36)0.1 (−11.4 to 11.6)0.99
 Lisinopril2.57 (1.53 to 4.33)11.8 (0.6 to 23)0.04
 Between-drug difference−0.01 (−0.10 to 0.08)11.8 (−2.3 to 25.9)0.10
 Heart rate–adjusted between-drug difference−0.01 (−0.10 to 0.09)14.6 (−0.3 to 29.5)0.06
  • Heart rate adjusted between drug differences indicates additional adjustment of each of the models for (1) baseline 44-hour heart rate and (2) treatment-induced change in 44-hour heart rate from baseline to 6 months. CVD, cardiovascular disease; SBP, systolic BP.